and drug products.

3) Responsibilities

The responsibilities of each team involved in the accelerated stability testing are as follows:

• Quality Control Team: To perform the stability testing as per the defined protocol and document the results.
• Research and Development Team: To design the
  

  “Unlock the Secrets of Drug Stability: Essential Guide for Pharmaceutical Scientists to Ensure Safe and Effective Medications”

  accelerated stability study protocol and provide input on critical quality attributes.
• Regulatory Affairs Team: To ensure the study complies with regulatory guidelines and provide relevant documentation for regulatory submissions.
• Stability Study Coordinator: To oversee the study, ensure adherence to protocols, and handle any deviations or unexpected results.

4) Procedure

The detailed stepwise procedure for conducting accelerated stability testing is outlined below:

1. Preparation of Stability Study Protocol:
1. 4.1 Define the objective, scope, and purpose of the study.
2. 4.2 Identify the drug substance or product to be tested and determine the critical quality attributes (CQAs) to be monitored.
3. 4.3 Specify the storage conditions (e.g., temperature, humidity) as per the ICH guidelines (e.g., 40°C ± 2°C and 75% RH ± 5% RH).
4. 4.4 Determine the frequency of testing and the parameters to be analyzed at each time point (e.g., appearance, assay, degradation products).
5. 4.5 Develop a comprehensive protocol outlining the procedures, equipment, and materials required.
2. Sample Preparation and Storage:
1. 4.6 Prepare the samples in their final packaging configuration, ensuring they are representative of the commercial product.
2. 4.7 Label each sample appropriately with the batch number, storage conditions, and time points.
3. 4.8 Store the samples in a designated stability chamber with controlled environmental conditions as per the study protocol.
3. Monitoring and Testing:
1. 4.9 At each defined time point (e.g., 1, 3, 6 months), retrieve samples from the stability chamber.
2. 4.10 Perform the required tests on each sample, such as appearance, assay, dissolution, degradation products, and any other critical quality attributes.
3. 4.11 Record the results in a stability testing log and compare them against predefined acceptance criteria.
4. Data Analysis and Interpretation:
1. 4.12 Analyze the test results to identify any trends or deviations in the quality attributes.
2. 4.13 Calculate the estimated shelf life of the drug product based on the degradation kinetics observed under accelerated conditions.
3. 4.14 Assess the data for compliance with regulatory requirements and guidelines.
5. Documentation and Reporting:
1. 4.15 Compile all data, test results, and observations into a comprehensive stability study report.
2. 4.16 Ensure the report includes a summary of the study design, test methods, results, and conclusions regarding the shelf life of the product.
3. 4.17 Submit the report to the relevant regulatory authorities or internal stakeholders as required.
6. Review and Conclusion:
1. 4.18 Conduct a final review of the study to confirm the accuracy and completeness of the data.
2. 4.19 Conclude the study by confirming the estimated shelf life and expiration date of the drug product based on the accelerated stability testing data.
3. 4.20 Make any necessary adjustments to the product’s storage conditions or formulation, if required, based on the findings.

5) Abbreviations, if any

• CQA: Critical Quality Attribute
• RH: Relative Humidity
• ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

6) Documents, if any

• Accelerated Stability Study Protocol
• Stability Testing Log Sheets
• Stability Study Report Template

7) Reference, if any

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• ICH Q1B: Photostability Testing of New Drug Substances and Products

8) SOP Version

Version 1.0